ELA MEDICAL'S CHORUS RM RATE RESPONSIVE PACEMAKER PRICED AT ABOUT $6,900
This article was originally published in The Gray Sheet
Executive SummaryEla Medical began shipping its Chorus RM dual-chamber rate responsive pacemaker and Opus RM single-chamber version at the end of March following FDA's March 10 approval of a single premarket approval application for the devices.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.